Evidence map›Paper›PMID 24983394›Full record

ReviewCurrent opinion in endocrinology, diabetes, and obesity2014

Early diabetic nephropathy in type 1 diabetes: new insights.

Petter Bjornstad, David Cherney, David M Maahs

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current opinion in endocrinology, diabetes, and obesity, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 1 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 1 synthesis or guideline pooled it, 115 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Novel Insights into Diabetic Kidney Disease.International journal of molecular sciences · 2024
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Petter BjornstadaDepartment of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA bDepartment of Medicine, Division of Nephrology, Toronto General Hospital, University of Toronto, Ontario, Canada cBarbara Davis Center for Diabetes, University of Colorado Denver, Aurora, Colorado, USA *David Cherney and David M. Maahs contributed equally to the writing of this article.
David Cherney
David M Maahs
University of Colorado Denver · USUniversity of Toronto · CA

Funding

SUBCLINICAL HEART DISEASE IN INSULIN-DEPENDENT DIABETESR01HL061753 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI REWERS, MARIAN J. · 1999 to 2007
$5.2M
A probabilistic closed-loop artificial pancreas to handle unannounced meals R01DK102188 · NIDDK · RENSSELAER POLYTECHNIC INSTITUTE · PI BEQUETTE, B. WAYNE, BUCKINGHAM, BRUCE A · 2014 to 2016
$1.0M
Cardiovascular disease in Type 1 melitus: Young adults to adolescentsK23DK075360 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI MAAHS, DAVID MATTHEW · 2007 to 2011
$663k
NCRR NIH HHS L40 RR018971NHLBI NIH HHS R01 HL061753NIDDK NIH HHS K23 DK075360NIDDK NIH HHS R01 DK102188
6 · The paper itself

Abstract

purpose of reviewDespite improvements in glycemic and blood pressure control in patients with type 1 diabetes, diabetic nephropathy remains the most common cause of chronic kidney disease worldwide. A major challenge in preventing diabetic nephropathy is the inability to identify high-risk patients at an early stage, emphasizing the importance of discovering new therapeutic targets and implementation of clinical trials to reduce diabetic nephropathy risk. RECENT

findingsLimitations of managing patients with diabetic nephropathy with renin-angiotensin-aldosterone system blockade have been identified in recent clinical trials, including the failure of primary prevention studies in T1D and the demonstration of harm with dual renin-angiotensin-aldosterone system blockade. Fortunately, several new targets, including serum uric acid, insulin sensitivity, vasopressin, and sodium-glucose cotransporter-2 inhibition, are promising in the prevention and treatment of diabetic nephropathy. SUMMARY: Diabetic nephropathy is characterized by a long clinically silent period without signs or symptoms of disease. There is an urgent need for improved methods of detecting early mediators of renal injury, to ultimately prevent the initiation and progression of diabetic nephropathy. In this review, we will focus on early diabetic nephropathy and summarize potential new therapeutic targets.

Indexed as

Angiotensin II Type 2 Receptor BlockersDiabetes Mellitus, Type 1Diabetic NephropathiesDisease ProgressionEarly DiagnosisGlycopeptidesHumansInflammationKidney Failure, ChronicRenin-Angiotensin SystemSodium-Glucose Transporter 2Uric AcidAngiotensin II Type 2 Receptor BlockerscopeptinsGlycopeptidesSodium-Glucose Transporter 2Uric Acid

Identifiers

PMID24983394
PMCPMC4138314
OpenAlexW2129601349

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.